Search
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Emricasan
go.drugbank.com/drugs/DB05408InvestigationalIt is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. … Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.
Cinnamon leaf oil
go.drugbank.com/drugs/DB16600InvestigationalMixtures: AXE BRAND HEAT OILSynonyms: Cinnamomum zeylanicum leaf oil, Cinnamomum verum leaf essential oilC31G
go.drugbank.com/drugs/DB05398InvestigationalC31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment … in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV).
TBC-3711
go.drugbank.com/drugs/DB05407InvestigationalTBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.
GTI-2501
go.drugbank.com/drugs/DB05406ExperimentalGTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.
Tosylchloramide
go.drugbank.com/drugs/DB14708InvestigationalTosylchloramide, also known as chloramine-T, is a chlorinated and deprotonated sulfonamide used as a mild disinfectant. It is not stable in the water dissolved form.
Categories: Compounds used in a research, industrial, or household setting